Last $29.99 USD
Change Today +0.03 / 0.10%
Volume 127.1K
As of 11:35 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8 Sylvan Way

Parsippany, NJ 07054

United States

Phone: 973-290-6000

Fax: 973-656-9898

The Medicines Company operates as a biopharmaceutical company. Marketed Products Angiomax Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. The company has exclusive license rights to develop, market, and sell Angiomax worldwide. Angiomax is approved in the United States for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA) and for patients undergoing percutaneous coronary intervention (PCI), with provisional use of glycoprotein IIb/IIIa receptor inhibitors, or GP IIb/IIIa inhibitors, including patients with or at risk of heparin induced thrombocytopenia and thrombosis syndrome (HIT/HITTS). Angiomax is approved in the European Union for use as an anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. The approval for acute coronary syndrome in Europe also includes treatment of adult patients with unstable angina or non-STEMI planned for urgent or early intervention, when used with aspirin and clopidogrel. In Europe, the company markets Angiomax under the tradename Angiox. Angiomax is also approved for use in Australia, Canada, New Zealand, Russia, India and other countries in Central America, South America and the Middle East for PCI indications similar to those approved by the the U.S Food and Drug Administration (FDA) or the European Medicines Agency (EMA). In addition, Angiomax is approved in Canada for the treatment of patients with HIT/HITTS undergoing cardiac surgery. Recothrom Recothrom is a topical human recombinant thrombin. In February 2013, pursuant to a master transaction agreement with Bristol-Myers Squibb Company (BMS), the company acquired the right to sell, distribute and market Recothrom on a global basis during the collaboration term, and BMS transferred to the company certain limited assets exclusively related to Recothrom, primarily the biologics license application (BLA) for Recothrom and certain related regulatory assets. Recothrom was approved by the FDA in 2008 and by Health Canada in 2010 for use as an aid to hemostasis to help control oozing blood and mild bleeding during surgical procedures. Cleviprex Cleviprex is an intravenous small molecule calcium channel blocker. The company licensed Cleviprex from AstraZeneca AB (AstraZeneca) in 2003 and has license rights to develop, market, and sell Cleviprex worldwide. The company received marketing approval for Cleviprex from the FDA in 2008 for the reduction of blood pressure when oral therapy is not feasible or not desirable. In addition to the United States and Switzerland, Cleviprex is approved for sale in Australia, Austria, Belgium, Canada, France, Germany, Luxembourg, the Netherlands, New Zealand, Spain and the United Kingdom with indications for blood pressure control in perioperative settings. Minocin IV The company markets Minocin IV in the United States. Minocin IV is an intravenous formulation of a tetracycline-class antibiotic that is approved in the United States for the treatment of infections due to various gram-negative bacteria, including Acinetobacter species. Minocin IV would be used particularly in instances when Acinetobacter is considered multidrug-resistant. Ready-to-Use Formulation Argatroban In 2009, the company licensed from Eagle Pharmaceuticals, Inc. (Eagle), marketing rights in the United States and Canada to a ready-to-use formulation of Argatroban developed by Eagle. Argatroban, which is marketed by GlaxoSmithKline and West-Ward Pharmaceuticals in a concentrated formulation and by Sandoz, a Novartis company, in two ready-to-use formulations, is approved as an anticoagulant in the United States for prophylaxis or the treatment of thrombosis in patients with or at risk for HIT and for patients with or at risk for HIT undergoing PCI. In 2011, the FDA approved Eagle's ready-to-use Argatroban for prophylaxis or treatment of thrombosis in adult patients with HIT and for use as an anticoagulant in adult patients with or at risk for HIT undergoing PCI.

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $29.99 USD +0.03

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.25 USD -0.005
CR Bard Inc $169.89 USD +2.22
CryoLife Inc $10.71 USD +0.11
Integra LifeSciences Holdings Corp $60.19 USD +0.12
Medicure Inc C$1.94 CAD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at